NYSE$PEN
Penumbra Inc · Q4 2024 earnings
Q4 2024 earnings · · After market close · Investor relations
Briefing
Penumbra reported revenue growth driven by strong U.S. thrombectomy sales but faced international revenue declines.
Penumbra's Q4 2024 revenue grew 10.8% YoY to $315.52 million, driven by strong U.S. thrombectomy sales (+27.3% YoY). Net income decreased by 37.85% YoY to $33.68 million. Gross margin improved to 66.8%, while operating margin expanded to 13.6%. International revenue declined 16.5% YoY due to lower sales in China.
- Revenue increased 10.8% YoY to $315.52 million.
- U.S. thrombectomy sales surged 27.3% YoY, while international revenue declined 16.5%.
- Gross margin improved to 66.8%, and operating margin expanded to 13.6%.
- Net income fell 37.85% YoY to $33.68 million due to higher operating expenses.
Headline financials
Revenue & EPS history
Penumbra · Revenue · Quarterly
$316M
Revenue by segment
Penumbra · $271M total across 2 segments · Q3 2023
- Thrombectomy$179M—66.1%
- Embolization and Access$91.9M—33.9%
Forward guidance
Penumbra expects 12%-14% revenue growth in 2025, driven by its U.S. thrombectomy franchise and expansion of its computer-assisted vacuum thrombectomy (CAVT) products.
Tailwinds
- 2025 revenue expected to grow between 12% and 14%.
- U.S. thrombectomy expected to grow 19%-20% YoY.
- Gross margin expected to exceed 67%.
- Operating margin expected to expand to 13%-14%.
- Continued investment in innovative thrombectomy technologies.
Headwinds
- International revenue remains under pressure due to declines in China.
- Higher operating expenses could impact profitability.
- Market competition in thrombectomy space increasing.
- Foreign exchange fluctuations may impact revenue growth.
- Potential supply chain constraints affecting production.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2024
+2.0%
Avg return
Earnings day
+1.3%
Avg return
5 days after
+1.9%
Avg return
30 days after
57%
28 / 49 earnings
Positive
+23.4%
Q4 2014
Best reaction
-15.8%
Q2 2018
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +0.1% | -0.7% | -1.1% | |
| Q4 2025 | +0.9% | +0.4% | -1.1% | |
| Q3 2025 | +17.1% | +24.0% | +33.3% | |
| Q1 2025 | +7.0% | +6.5% | -3.7% | |
| Q4 2024 | +12.0% | +6.1% | +3.4% | |
| Q3 2024 | +9.2% | +9.5% | +16.5% | |
| Q2 2024 | -6.3% | -1.6% | +13.5% | |
| Q1 2024 | -4.0% | +0.3% | -7.2% | |
| Q4 2023 | -7.7% | -10.1% | -13.0% | |
| Q3 2023 | +2.0% | +1.3% | +17.4% | |
| Q2 2023 | -11.2% | -16.8% | -12.8% | |
| Q1 2023 | +5.5% | +8.6% | +10.1% | |
| Q4 2022 | +2.3% | -0.5% | +5.1% | |
| Q3 2022 | +3.0% | +12.0% | +34.0% | |
| Q2 2022 | +13.7% | +8.7% | +12.5% | |
| Q1 2022 | -3.6% | -15.3% | -17.6% | |
| Q4 2021 | -3.4% | +5.6% | -2.6% | |
| Q3 2021 | +3.0% | -1.8% | -14.8% | |
| Q2 2021 | -2.1% | -2.4% | +3.0% | |
| Q1 2021 | -8.3% | -8.9% | -13.9% | |
| Q4 2020 | +3.2% | +1.6% | -3.4% | |
| Q3 2020 | +10.6% | +3.9% | -5.1% | |
| Q2 2020 | +2.5% | +5.5% | -3.5% | |
| Q1 2020 | +1.4% | +2.4% | +1.4% | |
| Q4 2019 | -6.8% | -10.0% | -13.7% | |
| Q3 2019 | -0.8% | +0.6% | +1.0% | |
| Q2 2019 | -6.9% | -6.5% | -15.1% | |
| Q1 2019 | +3.0% | -0.2% | +17.8% | |
| Q4 2018 | -11.2% | -5.7% | -1.1% | |
| Q3 2018 | +7.2% | +9.0% | +1.1% | |
| Q2 2018 | -15.8% | -16.0% | -3.8% | |
| Q1 2018 | +9.5% | +10.2% | +15.7% | |
| Q4 2017 | +3.9% | +8.4% | +11.0% | |
| Q3 2017 | +9.3% | +2.3% | -3.3% | |
| Q2 2017 | +5.8% | +4.1% | +4.4% | |
| Q1 2017 | +4.3% | -2.3% | +1.0% | |
| Q4 2016 | +3.8% | +5.2% | +7.8% | |
| Q3 2016 | -2.5% | +2.4% | -4.2% | |
| Q2 2016 | +10.9% | +10.8% | +6.6% | |
| Q1 2016 | -1.7% | — | — | |
| Q1 2015 | -1.7% | — | — | |
| Q2 2014 | -6.3% | — | — | |
| Q4 2015 | -6.3% | — | — | |
| Q4 2013 | -6.3% | — | — | |
| Q2 2015 | -6.3% | — | — | |
| Q1 2014 | -6.3% | — | — | |
| Q3 2014 | +23.4% | — | — | |
| Q3 2015 | +23.4% | — | — | |
| Q4 2014 | +23.4% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro